KRAS and cancer: This data, taken together, explain why vertical suppression of EGFR/MAPK pathway has only a transient effect in KRAS-driven colorectal cancers and stimulate new research on the best treatment approach for this aggressive cancer type, encouraging further evaluation of novel combination strategies including PI3K inhibitors.